GRI Bio, Inc. (NASDAQ:GRI) Short Interest Update

GRI Bio, Inc. (NASDAQ:GRI) saw a large drop in short interest in January. As of January 30th, there was short interest totaling 148,008 shares, a drop of 78.9% from the January 15th total of 700,747 shares. Based on an average daily trading volume, of 1,354,107 shares, the short-interest ratio is currently 0.1 days. Approximately 11.2% of the company’s stock are sold short. Approximately 11.2% of the company’s stock are sold short. Based on an average daily trading volume, of 1,354,107 shares, the short-interest ratio is currently 0.1 days.

GRI Bio Price Performance

NASDAQ GRI traded down $0.06 during trading hours on Tuesday, hitting $2.39. The company’s stock had a trading volume of 156,306 shares, compared to its average volume of 962,266. GRI Bio has a 12 month low of $2.19 and a 12 month high of $311.36. The company’s 50 day simple moving average is $11.88 and its two-hundred day simple moving average is $35.82. The company has a market cap of $3.47 million, a P/E ratio of -0.01 and a beta of -1.40.

GRI Bio (NASDAQ:GRI) last announced its quarterly earnings results on Friday, January 30th. The company reported $23.52 earnings per share (EPS) for the quarter. As a group, research analysts predict that GRI Bio will post -3.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GRI. Weiss Ratings reissued a “sell (e+)” rating on shares of GRI Bio in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of GRI Bio to a “strong sell” rating in a research report on Saturday, January 31st. Finally, Ascendiant Capital Markets raised their price objective on shares of GRI Bio from $980.00 to $1,008.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, GRI Bio presently has an average rating of “Hold” and an average target price of $644.00.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.